Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

• Conditions: SARS-COV-2

• Registration Number: NCT05075928
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-01
• Status Verified: 2021-10
• Study First Submitted: 2021-10-06
• Study First Submitted QC: 2021-10-06
• Study First Posted: 2021-10-13
• Primary Completion: 2021-11
• Study Completion: 2021-11
• Last Update Submitted: 2021-11-18
• Last Update Posted: 2021-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant	Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]

Trial Locations

Locations (1)

Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg; 🇫🇷 Strasbourg, France